Correction: Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5+ colorectal cancer

Cell Death Dis. 2020 Nov 23;11(11):1006. doi: 10.1038/s41419-020-03208-z.

Abstract

A Correction to this paper has been published: https://doi.org/10.1038/s41419-020-03208-z.

Publication types

  • Published Erratum